These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1109 related articles for article (PubMed ID: 8196915)

  • 1. Immunochemotherapy in B-16-melanoma-cell-transplanted mice with combinations of interleukin-2, cyclophosphamide, and PSK.
    Ueno Y; Kohgo Y; Sakamaki S; Itoh Y; Takahashi M; Hirayama Y; Niitsu Y
    Oncology; 1994; 51(3):296-302. PubMed ID: 8196915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
    Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
    J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma.
    Pica F; Fraschetti M; Matteucci C; Tuthill C; Rasi G
    Anticancer Res; 1998; 18(5A):3571-8. PubMed ID: 9858941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cure of B16F10 melanoma lung metastasis in mice by chronic indomethacin therapy combined with repeated rounds of interleukin 2: characteristics of killer cells generated in situ.
    Lala PK; Parhar RS
    Cancer Res; 1988 Mar; 48(5):1072-9. PubMed ID: 3124954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced antitumor immune responses of IL-2 gene-modified tumor vaccine by combination with IL-1 and low dose cyclophosphamide.
    Cao X; Zhang W; Wan T; Yu Y; Tao Q; Wang J
    J Exp Clin Cancer Res; 1999 Jun; 18(2):173-9. PubMed ID: 10464704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cure of human melanoma lung metastases in nude mice with chronic indomethacin therapy combined with multiple rounds of IL-2: characteristics of killer cells generated in situ.
    Lala PK; Elkashab M; Kerbel RS; Parhar RS
    Int Immunol; 1990; 2(12):1149-58. PubMed ID: 2090199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Krestin (PSK) on the induction of IL-2 activated killer cells.
    Sakamaki S; Kohgo Y; Nojiri S; Kanisawa Y; Ito Y; Takahashi M; Ueno Y; Hirayama Y; Niitsu Y
    Jpn J Clin Oncol; 1992 Apr; 22(2):79-83. PubMed ID: 1619782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrasplenic administration of interleukin-2 to potentiate specific chemoimmunotherapy in tumor-bearing mice.
    Nomi S; Naito K; Kahan BD; Pellis NR
    Cancer Res; 1986 Nov; 46(11):5606-10. PubMed ID: 2875791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amelioration of B16F10 melanoma lung metastasis in mice by a combination therapy with indomethacin and interleukin 2.
    Parhar RS; Lala PK
    J Exp Med; 1987 Jan; 165(1):14-28. PubMed ID: 3491867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
    Naito K; Pellis NR; Kahan BD
    Cancer Res; 1988 Jan; 48(1):101-8. PubMed ID: 3257158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The addition of interleukin-2 to cyclophosphamide therapy can facilitate tumor growth of B16 melanoma.
    Palomares T; Bilbao P; Alonso-Varona A; Barberá-Guillem E
    Cancer Immunol Immunother; 1995 May; 40(5):292-8. PubMed ID: 7600560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma.
    Teicher BA; Ara G; Buxton D; Leonard J; Schaub RG
    Clin Cancer Res; 1997 Sep; 3(9):1661-7. PubMed ID: 9815857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of hematologic and immunologic effects of high dose chemotherapy by interleukin-2 in a murine tumor model.
    Rinehart JJ; Triozzi PL; Lee MH; Aldrich W; Young D
    Mol Biother; 1992 Jun; 4(2):77-82. PubMed ID: 1515098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Regional adoptive immunotherapy using activated lymphocytes].
    Ebina T; Isono N; Murata K; Yokoyama J; Mikuni J; Ohuchi K
    Gan To Kagaku Ryoho; 1996 Sep; 23(11):1549-52. PubMed ID: 8854802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide.
    Hosokawa M; Sawamura Y; Morikage T; Okada F; Xu ZY; Morikawa K; Itoh K; Kobayashi H
    Cancer Immunol Immunother; 1988; 26(3):250-6. PubMed ID: 3260132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases.
    Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L
    Cancer Res; 1995 Nov; 55(21):4941-9. PubMed ID: 7585534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of the tumor determines the outcome of immunotherapy with interleukin-2, ABPP, and cyclophosphamide of micro- and macrometastatic intraperitoneal tumor.
    Eggermont AM; Sugarbaker PH
    Cancer Detect Prev; 1990; 14(4):483-90. PubMed ID: 2224911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of pretreatment with lentinan or krestin on antitumor effector cell activities suppressed by cyclophosphamide].
    Yang ZB
    Hokkaido Igaku Zasshi; 1994 Jan; 69(1):137-45. PubMed ID: 8119654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of hyaluronan inhibits IL-2-induced vascular leak syndrome and maintains effectiveness of IL-2 treatment for metastatic melanoma.
    Guan H; Nagarkatti PS; Nagarkatti M
    J Immunol; 2007 Sep; 179(6):3715-23. PubMed ID: 17785808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.